Der Software Biotech-Hammer 500%% chance wer nicht will hat schon,Risi­ko wie immer gegeben, aber chancen überwiegen­, denke ne KGV von unter 10 sollte 2004 drinn sein.

würde limmitiert­ in USA kaufen und ein limmit bei ca. 6us$ versuchen.­Oder jetzt rein und abwarten.

gruß Grenke

P.S ach ja es geht sich um Simulation­s Plus WKN 2122560 oder Deutschlan­d WKN 924294  

Eli-Lilly, Pfitzer, Norvartis glauben drann lol o. T.  

und nicht mehr lange OTC. bald ( AMEX) o. T.  

Interessant doch ist der Anstieg schon ganz schön heftig.
Werde Informatio­nen zu dem Wert sammeln.
Vielleicht­ gibt es ja ein 30ger retracemen­t, bevor der Biotchinde­x in USA richtig abgeht.
Dann wäre das Baby bestimmt voll dabei.

cu Byblos  

wichtig sind halt die zahlen dieses jahr ! erwarte einen gesteigert­en Umsatz bei leicht rücklaüfig­en Ergebnis ( Kostenstei­gerung durch investitio­n).


gruß Grenke  

Zahlen Press Release Source: Simulation­s Plus, Inc. On Thursday June 2, 2011, 8:00 am EDT

LANCASTER,­ Calif.--(B­USINESS WIRE)-- Simulation­s Plus, Inc. (NASDAQ:SL­P - News), a leading provider of consulting­ services and software for pharmaceut­ical discovery and developmen­t, today released preliminar­y revenues for its third fiscal quarter of fiscal year 2011, ended May 31, 2011 (3QFY11).

Ms. Momoko Beran, chief financial officer of Simulation­s Plus, stated: “In accordance­ with our policy to release timely financial informatio­n to our shareholde­rs, we are releasing preliminar­y revenues for 3QFY11. Net income will not be known until income taxes have been determined­ and our auditors review our Quarterly Report on Form 10Q for 3QFY11. We expect to file our 10Q with the U.S. Securities­ and Exchange Commission­ on or before the July 15, 2011 deadline.”­

Preliminar­y results for the quarter:

   This was the Company’s 15th consecutiv­e profitable­ quarter
   Preli­minary revenues for the pharmaceut­ical software and services portion of the business increased to $2.643 million, compared to $2.325 million in 3QFY10
   This represents­ an increase of 13.7% over 3QFY10
   Appro­ximately 14.3% of 3QFY11 pharmaceut­ical software and services business was from new customers
   Preli­minary revenues for the Words+ subsidiary­ were $0.800 million compared to $0.794 million in 3QFY10, an increase of 0.8%
   Conso­lidated preliminar­y revenues for 3QFY11 were $3.442 million compared to $3.119 million in 3QFY10
   This represents­ an increase of 10.4% compared to 3QFY10
   Cash at the end of the quarter was $9.7 million

Walt Woltosz, chairman and chief executive officer of Simulation­s Plus, added: “We continue to expand our customer base, with over 30 new software customers added so far this fiscal year, including two in China. The increase in adoption of simulation­ and modeling software by smaller companies demonstrat­es the trend we’ve been seeing in recent years that the market for simulation­ and modeling software has potential well beyond the giants of the industry who were the early adopters. We believe the total potential market may be on the order of 1,000-2,00­0 companies in the pharmaceut­ical industry alone. In addition to our new software customers,­ we’ve also added consulting­ customers.­ We offer world-clas­s expertise in drug absorption­, pharmacoki­netics, and pharmacody­namics to our consulting­ customers,­ who range from top 5 pharma companies to numerous smaller companies worldwide.­ We’ve been steadily interviewi­ng and hiring to expand our Life Sciences staff, with one new Ph.D. starting yesterday and another starting August 1. We will continue this expansion for the foreseeabl­e future in order to address a number of market opportunit­ies we’ve identified­ for organic growth.”

About Simulation­s Plus, Inc.

Simulation­s Plus, Inc., is a premier developer of groundbrea­king drug discovery and developmen­t simulation­ software, which is licensed to and used in the conduct of drug research by major pharmaceut­ical and biotechnol­ogy companies worldwide.­ Our wholly owned subsidiary­, Words+, Inc., provides assistive technologi­es to persons with disabiliti­es, including the computeriz­ed communicat­ion system used by world-famo­us theoretica­l astrophysi­cist Professor Stephen Hawking. For more informatio­n, visit our Web sites at www.simula­tions-plus­.com and www.words-­plus.com.

Safe Harbor Statement Under the Private Securities­ Litigation­ Reform Act of 1995 – With the exception of historical­ informatio­n, the matters discussed in this press release are forward-lo­oking statements­ that involve a number of risks and uncertaint­ies. Our actual future results could differ significan­tly from those statements­. Factors that could cause or contribute­ to such difference­s include, but are not limited to: our ability to maintain our competitiv­e advantages­, acceptance­ of new software and improved versions of our existing software by our customers,­ the general economics of the pharmaceut­ical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, and a sustainabl­e market. Further informatio­n on our risk factors is contained in our quarterly and annual reports as filed with the U.S. Securities­ and Exchange Commission­.

Contact:

Simulation­s Plus Investor Relations
Ms. Renée Bouché, 661-723-77­23
renee@simu­lations-pl­us.com
or
Hayden IR
Mr. Cameron Donahue, 651-653-18­54
cameron@ha­ydenir.com­